kidney disease

R&D

Xenotransplantation at the brink of breakthrough: A new era ...

In a landmark procedure performed at Massachusetts General Hospital (MGH) on 25th January 2025, a 66-year-old man with end-stage renal disease (ESRD) received a genetically modif

News

Novartis gets FDA nod for second of three IgAN drugs

Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy.

News

Fabhalta is first FDA-approved therapy for rare disease C3G

Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.

News

Two more biotechs, Metsera and Maze, cross IPO finish line

Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.

News

dialysis machine at patient hospital bedside

Baxter slims down again, selling kidney division to Carlyle

Baxter International has agreed to sell its kidney treatment division to private equity firm Carlyle Group in a $3.8 billion cash deal, continuing its efforts to streamline its operations a

News

Novartis gets FDA OK for first in its trio of IgAN therapies

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug.

Xenotransplantation at the brink of breakthrough: A new era ...

Novartis gets FDA nod for second of three IgAN drugs

Fabhalta is first FDA-approved therapy for rare disease C3G

Two more biotechs, Metsera and Maze, cross IPO finish line

Baxter slims down again, selling kidney division to Carlyle

Novartis gets FDA OK for first in its trio of IgAN therapies

CDMOs: Their crucial role and how to select one, with Sigma ...

How to meet your physicians where they are online

kidney disease

Editor's Picks